Abstract
Over the last two decades the value and safety of monocyte derived dendritic cell (Mo-DC) vaccines in the context of cancer immunotherapy have been shown in several clinical studies. In parallel, a multitude of different maturation and antigen loading protocols has been developed leading to cellular products with different therapeutic efficacy. One of the critical factors in this context is the immunological fitness of the patient that might lead to generation of functionally impaired Mo-DCs. Both the functional characteristics and cross-presentation capacity of patients‘ Mo-DCs can be improved by mRNA electroporation. However, standardized and reproducible GMP-compliant manufacturing of such cellular products requires instrumentation with specific characteristics that are not always addressed by conventional technologies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
